Jones ER, O’Flynn H, Njoku K, Crosbie EJ. Detecting endometrial cancer. Obstet Gynaecol. 2021;23(2):103–12.

Google Scholar 

Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022;10(1).

Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12–39.

PubMed  Google Scholar 

Kelkar SS, Prabhu VS, Corman S, Odak S, Rusibamayila N, Macahilig C, et al. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States. Gynecol Oncol. 2023;169:154–63.

PubMed  Google Scholar 

Cao W, Ma X, Fischer JV, Sun C, Kong B, Zhang Q. Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomark Res. 2021;9(1):49.

PubMed  PubMed Central  Google Scholar 

Mittica G, Ghisoni E, Giannone G, Aglietta M, Genta S, Valabrega G. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget. 2017;8(52):90532–44.

PubMed  PubMed Central  Google Scholar 

European Medicines Agency. JEMPERLI (dostarlimab) Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf2025.

National Institute for Health and Care Excellence [NICE]. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer: Draft guidance 2025 Available from: https://www.nice.org.uk/guidance/gid-ta11340/documents/draft-guidance.

National Institute for Health and Care Excellence [NICE]. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency 2022 Available from: https://www.nice.org.uk/Guidance/Ta779/Chapter/3-Committee-Discussion.

European Medicines Agency. LENVIMA (lenvatinib) Summary of Product Characteristics 2024 Available from: https://www.ema.europa.eu/en/documents/product-information/lenvima-epar-product-information_en.pdf.

O’Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus AA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: Results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752–61.

PubMed  PubMed Central  Google Scholar 

Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–48.

PubMed  PubMed Central  Google Scholar 

Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159–70.

PubMed  PubMed Central  Google Scholar 

Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The Phase III DUO-E trial. J Clin Oncol. 2023:Jco2302132.

Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, et al. Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: Interim results of the Phase I GARNET study. Clin Cancer Res. 2023;29(22):4564–74.

PubMed  PubMed Central  Google Scholar 

Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: A nonrandomized Phase 1 clinical trial. JAMA Oncol. 2020;6(11):1766–72.

PubMed  Google Scholar 

Colombo N, Harano K, Hudson E, Galli F, Antill Y, Choi CH, et al. LBA40 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma. Ann Oncol. 2023;34:S1281–2.

Google Scholar 

Mirza MR, Coleman RL, Hanker L, Slomovitz B, Valabrega G, DeMars L, et al. 820TiP ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: A phase III, randomized, double-blind, study of dostarlimab + carboplatin-paclitaxel followed by dostarlimab + niraparib versus placebo (PBO) + carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC). Ann Oncol. 2021;32:S770–1.

Google Scholar 

Mirza MR, Coleman RL, Hanker LC, Slomovitz BM, Valabrega G, Im E, et al. ENGOT-EN6/NSGO-RUBY: A phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC). J Clin Oncol. 2020;38(15_suppl):TPS6107-TPS.

Heffernan K, Nikitas FS, Shukla U, Camejo HS, Knott C. Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis. Gynecol Oncol. 2022;166(2):317–25.

PubMed  Google Scholar 

Office For National Statistics. Population estimates for England and Wales: mid-2022 Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/populationestimatesforenglandandwales/mid2022#:~:text=Source%3A%20Population%20estimates%20from%20the%20Office%20for%20National%20Statistics,-Embed%20code&text=At%20mid%2D2022%2C%20there%20were,and%200.9%25%2C%20respectively.

"R CORE Team". R: a language and environment for statistical computing. The R Project for Statistical Computing 2020 Available from: https://cran.r-project.org/bin/windows/base/old/4.0.2/.

National Institute for Health and Care Excellence [NICE]. Testing strategies for Lynch syndrome in people with endometrial cancer 2020 [updated 28 October 2020. Available from: https://www.nice.org.uk/Guidance/Dg42.

Mevius A, Karl F, Wacker M, Welte R, Krenzer S, Link T, et al. Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis. J Cancer Res Clin Oncol. 2023;149(5):1929–39.

PubMed  Google Scholar 

Berg HF, Engerud H, Myrvold M, Lien HE, Hjelmeland ME, Halle MK, et al. Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value. Br J Cancer. 2023;128(4):647–55.

PubMed  Google Scholar 

Kim SR, Pina A, Albert A, McAlpine JN, Wolber R, Gilks B, et al. Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers. Int J Gynecol Cancer. 2020;30(6):783–8.

PubMed  Google Scholar 

Mirza MR, Chase DM, Slomovitz BM, dePont CR, Novák Z, Black D, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145–58.

PubMed  Google Scholar 

Goulden S, Heffernan K, Sen Nikitas F, Shukla U, Knott C, Hunger M, et al. Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England. Int J Gynecol Cancer. 2023;33(11):1715–23.

PubMed  PubMed Central  Google Scholar 

Banerjee S, Ingles Russo Garces A, Garside J, Rahman T, Pearson C, Heffernan K. Real-world patient characteristics and survival outcomes in patients with advanced or recurrent endometrial cancer in England: a retrospective, population-based study. BMJ Open. 2024;14(11):e083540.

Illah O, Adeeko D, Olaitan A, Gentry-Maharaj A. Racioethnic Disparities in Endometrial Cancer Outcomes. Diagnostics (Basel). 2024;14(4).

Moss EL, Teece L, Darko N. Uterine cancer mortality and Black women: time to act. Lancet Oncol. 2023;24(6):586–8.

PubMed  Google Scholar 

Shiekh SI, Harley M, Ghosh RE, Ashworth M, Myles P, Booth HP, et al. Completeness, agreement, and representativeness of ethnicity recording in the United Kingdom’s Clinical Practice Research Datalink (CPRD) and linked Hospital Episode Statistics (HES). Popul Health Metr. 2023;21(1):3.

PubMed  PubMed Central  Google Scholar 

Wesselbaum A, Wallis J, Luhar S, Tunaru F, Carpenter L, Schneider D, et al. P-038. A real-world study of patients with advanced/recurrent endometrial cancer across England and Scotland. 2024 Available from: https://www.bgcs.org.uk/wp-content/uploads/2024/07/BGCS-2024-Book-of-Abstracts.pdf.

European Medicines Agency. KEYTRUDA (pembrolizumab) Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf Accessed 14 October 2024.2025.